Abstract
We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log10 IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations. The patient achieved sustained virological success (serum HBV DNA <12 IU/ml) when tenofovir was added to the treatment. This case highlights the difficulty in choosing an optimal therapy in such specific conditions and supports the concept of tailoring therapy (including combination regimens) on the basis of the particular conditions of each individual patient.
This is a preview of subscription content, log in via an institution to check access.
References
Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation. 2000;70:809–15.
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.
Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther. 2003;8:531–4.
Chang TT, Gish RG, De Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.
Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Xu D, Cross A, Tenney DJ. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. J Hepatol. 2007;46:S294.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.
Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.
Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. Hepatitis B virus DNA Levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72–84.
Rodriguez-Frias F, Jardi R, Schaper M, Buti M, Ferrer-Costa C, Tabernero D, Homs M, Esteban R. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther. 2008;13:991–9.
Chen WN, Oon CJ. Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high anti-hepatitis B virus antibody levels but negative for HBsAg. J Clin Microbiol. 2000;38:2793–4.
Khokhar A, Afdhal NH. Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med. 2008;121:S33–44.
Rodriguez C, Chevaliez S, Pallier C, Pawlotsky JM. Ultra-deep sequencing analysis demonstrates pre-existence of HBV resistance substitutions at baseline in patients who subsequently develop clinical resistance. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, CA, February 2010, paper # 170LB.
Bagaglio S, Porrino L, Lazzarin A, Morsica G. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection. 2010;38:417–21.
Bagaglio S, Bianchi G, Danise A, Porrino L, Uberti-Foppa C, Lazzarin A, Castagna A, Morsica G. Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection. 2011;39:121–6. Epub 2011 Mar 22.
Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718–26.
Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275–85.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarrecchia, C., Svicher, V., Volpi, A. et al. Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. Infection 39, 367–370 (2011). https://doi.org/10.1007/s15010-011-0127-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-011-0127-3